

Stem Cell Therapy for End Stage Liver Disease

Essay

Submitted for Partial Fulfillment of Master Degree in
Tropical Medicine

Submitted by

Tawfik Abdullah Abualrejal
(M.B.B.ch)

Faculty of Medicine Cairo University

Supervised by

Prof. Hosny Mohamed Salama

Professor of Tropical Medicine Cairo University

Prof. Abd Alrahman Nabwe Zekri

Professor of Virology and Immunology, Cancer Biology
Department, National Cancer Institute, Cairo University

Dr. Rasha Ahmed Abdalazez

Assistent Professor of Tropical Medicine Cairo University

Faculty of Medicine

Cairo University

2010

Abstract

Stem cells are undifferentiated cells characterized by self renewal, multipotency, long term tissue repopulation after transplantation, serial transplant ability and when divide the daughter cell can either fully differentiated or remain stem cell. Haematopoietic stem cells can be differentiated into hepatocytes, cardiomyocytes, brain cells, hair follicles and sebaceous glands, epithelial and nonepithelial cell types in the kidney, islet cells in pancreas, type II pneumocytes in the lungs, mucous secreting cells in the stomach, goblet cells and enteroendocrine cells in the intestine. For treatment of genetic diseases, transplantation of genetically modified autologous marrow would avoid many of the risks of allogenic transplants. It is used in treatment of many diseases as cystic fibrosis, Duchenne muscular dystrophy, immunodeficiency diseases, some types of anemias like thalassemia and sickle cell anemia and wound healing, gastrointestinal diseases and autoimmune diseases. Hepatocyte transplantations have been performed for a variety of indications, including inborn errors of metabolism. Cells derived from other tissues, such as bone marrow, monocytes, endothelium, and pancreas, are also being explored as potential therapies for liver based metabolic disorders.

Stem cells are not only units of biological organization, responsible for the development and the regeneration of tissue and organ systems, but are also targets of carcinogenesis. Bone marrow stem cells can be used to accelerate liver regeneration before extended hepatectomy for hepatocellular carcinoma.

Key words: Stem cells, Haematopoietic stem cells, genetic diseases,
Hepatocyte cell transplantation

Acknowledgment

First of all, thanks to GOD for his grace and mercy, and for giving me the effort to complete this work.

It was an honor to work under the supervision of eminent professors, who I appreciate their wholehearted support. To them, I owe more than I can record.

I was fortunate enough to carry out this work under the supervision of Prof. Dr. Hosny Salama, Professor of Tropical Medicine, at Cairo University. His care, perfectionism and invaluable experience were of much guidance to me. He sincerely supported me throughout this work and offered help to overcome every difficulty I faced. Thanks for always being a father before being a teacher.

I would like to express my gratitude and thanks to Prof. Dr. Abdel-Rahman Zekri, Professor of Immunology and Virology, National Cancer Institute for guidance during writing this essay. He gave me much of his time, experience and support. His valuable comments, efforts and collaboration were the causes to complete this work properly.

Words will never be able to express my deepest gratitude and appreciation to Prof. Dr. Eman Medhat Hassan Professor of Tropical Medicine Cairo University for her strict supervision and revision of this work. She gave me much of her time, experience and support.

Also Words will never be able to express my deepest gratitude and appreciation to Dr. Rasha Ahmed assistant professor of Tropical Medicine, Cairo University for her strict supervision and revision of this work. She gave me much of her time, experience and support.

I also extend my thanks and appreciation to the head of Tropical Medicine department and all the staff members for their noble attitude and kind help.

Table of Contents

List of tables	IV
List of figures.....	V
List of abbreviations	VI
Introduction	1
Aim of the work.....	6
Review of Literature.....	

• Chapter One

1. End Stage Liver Disease

1.1	Epidemiology of hepatic cirrhosis.....	8
1.2	Etiologies of hepatic cirrhosis	8
1.3	Pathogenesis of hepatic cirrhosis	10
1.4	Complications of hepatic cirrhosis.....	12
1.4.1	Portal Hypertension and Variceal Bleeding.....	12
1.4.2	Ascites	14
1.4.3	Spontaneous Bacterial Peritonitis.....	14
1.4.4	Hepatorenal syndrome.....	17
1.4.5	Hepatic Encephalopathy.....	18
1.4.6	Hepatocellular carcinoma.....	20
1.5	Prognosis of chronic liver diseases	
1.6	Treatment options of End Stage Liver disease.....	24
1.6.1	General treatment.....	24
1.6.2	Liver transplantation.....	26
1.6.3	Hepatocellular transplantation	30

• Chapter two

2 Stem cell

2.1	Definition of stem cells.....	34
2.2	Classification and nomenclature – of stem cells.....	35

2.2.1 Embryonic stem cells.....	38
2.2.1.1 Sources of embryonic cells.....	41
2.2.2 ADULT STEM CELLS	
2.2.2.1 Differences between adult and embryonic stem cells.....	43
2.2.2.2 Regulation of differentiation of adult stem cells.....	44
2.2.3 Haematopoietic stem cells:	
2.2.3.1 Haematopoietic cell development.....	47
2.2.3.2 Cell markers on haematopoietic stem cells.....	48
2.2.3.3 Sources of haematopoietic stem cells.....	50
2.2.3.4 Procedures of peripheral blood stem cell mobilization....	53
 • <u>Chapter three</u>	
3. Hepatic Stem Cells	64
3.1 Hepatocytes as hepatic stem cells	66
• Stages of regeneration.....	66
• Growth factors.....	68
3.2 Intrahepatic stem cells.....	69
• Stem cells during liver embryologic development.....	69
• Stem cells in adult liver.....	73
• Oval cells.....	74
• Small hepatocyte like progenitor cells.....	77
3.3 Extrahepatic sources of hepatobiliary cells.....	79
• Bone marrow stem cells populate the liver.....	79
3.4 Regulation of bone marrow stem cell homing to the liver:.....	86
• Release of HSC from the bone marrow.....	86
• Hepatic recruitment of HSCs in liver injury.....	90
3.5 Mechanism of conversion of bone marrow stem cells to hepatocytes.....	93

3.6. Clinical applications of stem cells.....	116
3.7 Clinical Trials.....	118
3.7.1 Clinical trials in different diseases.....	118
3.7.1.1 Regenerative medicine (Cell based therapy).....	118
3.7.1.2 Genetic disease.....	119
3.7.1.3 haematological diseases.....	120
3.7.1.4 Gene Therapy.....	121
3.7.1.5 Cancer.....	123
• <u>Chapter four</u>	
4. Clinical application of stem cells.....	126
4.1 Ethics in stem cell research and therapy.....	126
4.2 clinical trials.....	127
4.3 Egyptian trials of stem cell transplantation in liver diseases	143
Summary and conclusions.....	155
References.....	161
Arabic Summary.....	

List of Tables

Table		Page
Table (1)	Etiologies of hepatic cirrhosis	9
Table (2)	Pugh modification of the Child-Turcotte classification	22
Table (3)	MELD score and its derivatives	23
Table (4)	Indications for liver transplantation	27
Table (5)	Disorders considered amenable to liver-directed cell therapy	31
Table (6)	Sources of embryonic stem cells	41
Table (7)	Differences between human adult stem cells and embryonic stem cells	43
Table (8)	Proposed cell surface markers of undifferentiated HSCs	50
Table (9)	PB versus BM as a source of haematopoietic progenitor cells for transplantation	52

List of Figures

No.		Page
Fig. (1)	Barcelona clinic liver cancer staging classification and treatment schedule	19
Fig. (2)	Clinical stages of cirrhosis according to clinical features: yearly rates of progression and death	21
Fig. (3)	Classification of human stem cells	36
Fig. (4)	Embryonic stem cells	39
Fig. (5)	Possible explanations for the perceived plasticity	45
Fig. (6)	Schematic representation of haematopoietic cell development	47
Fig. (7)	Mechanism of action of G-CSF and AMD3100	54
Fig. (8)	Advantage of bone marrow over cord blood transplantation	63
Fig. (9)	Advantage of cord blood over bone marrow transplantation	63
Fig. (10)	Summary of interaction between hepatic stem cells	65
Fig. (11)	Multistep model of liver regeneration	67
Fig. (12)	Schematic diagram of fetal liver development in the mouse	72
Fig. (13)	Diagram outlining the differentiation and commitment of the hepatic-related cells from their early stages in development through adulthood	78
Fig. (14)	Stem cell trafficking in liver injury	92
Fig. (15)	Distinguishing differentiation from fusion by cytogenetic analysis based on identifying sex chromosomes	95
Fig. (16)	Models of differentiation of HSCs into hepatocytes	96
Fig. (17)	Malignant transformation of BMSCs to HCC	98
Fig(18)	Pathogenesis of cirrhosis and possible interventions of MSC	100
Fig(19)	stem cell plasticity	117
Fig(20)	Potential uses of bone marrow-derived stem cells to treat liver disease and possible routes of inoculation	131

List of Abbreviations

2-AAF	2-acetylamino-fluorene
ABMI	Autologous bone marrow cell infusion
AFP	Alpha fetoprotein
AGM	Aortogonadal mesonephros
α1-AT	α 1-antitrypsin
AW	Adeno-associated viral vectors
BCLC	Barcelona clinic liver cancer
BFU-E	Burst forming unit-Erythroid
BM	Bone marrow
BMSCs	Bone marrow stem cells
BMT	Bone marrow transplantation
CAFC	Cobble stone area forming cells
CD	Cluster of differentiation
CDKs	Cyclin dependent kinases
CFC	Colony forming cells
CFC-Mix	Colony forming cells-mixed erythroid colonies
CFU-E	Colony forming unit- Erythroid
CFU-GM	Colony forming unit- Granulocyte, Macrophage
CFU-S	Colony forming unit-spleen
CK	Cytokeratin
CLD	Chronic liver diseases
CSPH	Clinically significant portal hypertension
CTP	Pugh modification of Child Turcotte classification
DMSO	Dimethyl sulfoxide
ECM	Extracellular matrix
ED	Embryonal day
ELTC	Extended long term culture
Eo-CFC	Eosinophil- Colony forming cells
EPC	Endothelial progenitor cell
Epo	Erythropoietin
ERK-1&2	Extracellular signal-regulated kinases 1 and 2
ES cells	Embryonic stem cells
FAH	Fumaryl acetoacetate hydrolase
FAK	Focal adhesion kinase
FGFs	Fibroblast growth factor-2
GM-CSF	Granulocyte, macrophage colony stimulating factor
GST	Glutathione-S-transferase

GVHD	Graft versus host disease
HCV	Hepatitis C virus
HCC	Hepatocellular carcinoma
HE	Hepatic encephalopathy
HGFs	Haematopoietic growth factors
HPC	Haematopoietic progenitor cells
HRS	Hepatorenal syndrome
HSCs	Haematopoietic stem cells
HVPG	Hepatic venous pressure gradient
IL	Interleukin
INR	International normalized ratio
IVF	In vitro fertilization
kDa	Kilo Dalton
UK	Leukemia inhibition factor
LPSCs	Liver progenitor/stem cells
LTC-IC	Long term culture initiating cells
MAPC	Multipotent adult progenitor cells
M-CSF	Macrophage colony stimulating factor
MDR-1	Multidrug resistance gene-1
Meg-CFC	Megakaryocyte- Colony forming cells
MELD	Model for end-stage liver disease
MGI-2A	Macrophage-granulocyte inducing factor 2A
MHC	Major histocompatibility complex
MIP-1β	Macrophage inhibitory protein-1 β
MIP-1α	Macrophage inhibitory protein- 1 α
MNCs	Mononuclear cells
M2-PK	Pyruvate kinase
MSCs	Mesenchymal stem cells
NAFLD	Non alcoholic fatty liver disease
NOD/SCID	Non-obese diabetic severely immunodeficient mice

NTCB	2-nitro 4-trifluoro-methylbenzyl-1, 3 cyclohexanedion
OLT	Orthotopic liver transplantation
PB	Peripheral blood
PBPCs	Peripheral blood progenitor cells
PBSCs	Peripheral blood stem cells
PDGF	Platelet derived growth factor
PDGFR	Platelet derived growth factor receptor
PECAM	platelet endothelial cell adhesion molecule
PF-4	platelet factor 4
PHx	partial hepatectomy
PKC	protein kinase C
PMN	polymorphonuclear leucocytes
PPG	portal pressure gradient
Pyk-2	proline-rich tyrosine kinase 2
RTK	Receptor tyrosine kinase
SBP	Spontaneous bacterial peritonitis
SCF	Stem cell factor
SCNT	Somatic cell nuclear transfer
SDF-1	Stromal derived growth factor
SRC	SCID repopulating cells
TRF	Telomere restriction fragment
TSSC	Tissue-specific stem cells
UCB	Umbilical cord blood
VCAM-1	Vascular endothelial cell adhesion molecule
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VLA	Very late antigen

Introduction

End stage liver disease is the final stage of acute or chronic liver damage and is irreversibly associated with liver failure. End stage liver disease can develop rapidly, over days or weeks (acute and sub-acute liver failure, respectively), or gradually, over months or years (chronic liver failure) (*Heidelbaugh 2006*).

In Egypt the high incidence of HCV infection the legacy left from the mass use of tartar emetic to eradicate schistosomiasis, as in other high prevalence areas will take years to reduce. Steatohepatitis due to non-alcoholic fatty liver disease is developing into a new and major health problem as a result of rising levels of obesity in populations worldwide. Hepatic steatosis also has an adverse influence on the progression of other liver diseases including chronic HCV infection and alcoholic liver disease. In many countries, considerable public concern is on the rise due to increased levels of alcohol consumption adversely affecting younger and affluent age groups. With the rising prevalence of cirrhosis, primary hepatocellular carcinoma (HCC) is increasing in frequency as is that of primary intrahepatic cholangiocarcinoma. (*Williams 2006*.)

Currently, liver transplantation is the most effective therapy for patients with end stage liver disease (*Francoz et al., 2007*). However, its potential benefits are hampered by many drawbacks, such as the relative shortage of donors, operative risk, post-transplant rejection, recidivism of the pre-existing liver disease, and high costs.

In an Egyptian experience for living related liver transplantation recipient and graft survivals were 86.6% at the end of the follow-up which was comparable to literature reports for deceased donor liver transplantation. Clinical HCV recurrence was observed in 10/38 patients (26.3%). Four patients developed mild fibrosis with a mean fibrosis score of 0.6 and mean grade of histological activity index of 7.1. None of the recipients developed allograft cirrhosis during the mean follow-up period of 16 +/- 8.18 months (range, 4-35 months). Estimated and actual graft volumes were negatively correlated with the incidence and early clinical HCV recurrence. None of the other risk factors were significantly correlated with clinical HCV recurrence: gender, donor and recipient ages, pretransplantation Child-Pugh or model for end-stage liver disease (MELD) scores, pre- and postoperative viremia, immunosuppressive drugs, pulse steroid therapy, and preoperative anti-HBc status. Which made them conclude that postoperative patient and graft survival rates for HCV (genotype 4)-related cirrhosis were more or less comparable to DDLT reported in the literature. Clinical HCV recurrence after LDLT in our study was low. Small graft volume was a significant risk factor for HCV recurrence. A longer follow-up and a larger number of patients are required to clarify these issues (*Yosry et al., 2008.*)

In this scenario, stem cell therapy sounds particularly attractive for its potential to support tissue regeneration requiring minimally invasive procedures with few complications. This field of research, which represents the ground from which the new discipline of “regenerative medicine” has germinated, has rapidly developed in recent years, arising great interest among scientists and physicians, and frequently appearing in newspapers

headlines touting miracle cures, but arising ethical crises as well (*Mimeault et al., 2007.*)

Preliminary experience with clinical hepatocyte transplantation during the past decade has provided proof of concept that cell therapy can be effective for the treatment of some liver diseases. Recent progress in cell biology resulting in the isolation and characterization of bone marrow stem cells and progenitor cells further increases the expectation for a new approach to the treatment of genetic and chronic liver disease (*Sakaida et al., 2005.*)

There are at least two types of stem cells in the human bone marrow; mesenchymal stem cells, and hematopoietic stem cells (HSCs). HSCs are CD34⁺ and CD133⁺ and they can give rise to all lineages of blood cell differentiation. Recently, intracoronary infusion of bone marrow stem cells was reported to be safe and effective in patients with acute myocardial infarction (*Schachinger et al., 2006*)

Furthermore, *in vivo* trans-differentiation of human HSCs to functional hepatocytes has been demonstrated (*Almeida-Porada et al., 2004*). Also, it has been shown that infusion of bone marrow stem cells to animal models of liver cirrhosis can lead to regression of liver fibrosis (*Sakaida 2004*) . Recently, (*am Esc et al., 2005*)reported that portal administration of autologous CD133⁺ HSCs accelerated liver regeneration. We hypothesized that infusion of HSCs may help to reverse liver failure in patients with decompensated cirrhosis.

The most debated issue pertains to the use of human ESCs, as it implies, with current technologies, the destruction of human embryos. Opponents of ESC research argue that ESC research represents a slippery slope to reproductive cloning, and can fundamentally devalue human life. Contrarily, supporters argue that such research should be pursued because the resultant treatments could have significant medical potential. It is also noted that excess embryos created for *in vitro* fertilization could be donated with consent and used for the research(**Furcht 2008**)

The ensuing debate has prompted authorities around the world to seek regulatory frameworks and highlighted the fact that stem cell research represents a social and ethical challenge. Thus, current legislation on ESC use widely varies, with some countries being more permissive (such as UK, Netherlands, Spain and France) than others (such as North America and most of the North European countries) (**Furcht .,2008.**)

In Japan (**Terai et al 2006**) reported his result done on nine liver cirrhosis patients that underwent autologous bone marrow cell infusion (ABMI) from the peripheral vein. Subjects were patients with LC with total bilirubin of less than 3.0 mg/dl, platelet count of more than 50 % and no viable hepatocellular carcinoma on diagnostic imaging. Autologous bone marrow (BM; 400 ml) was isolated from the ilium under general anesthesia. Mononuclear cells (MNCs) were separated by cell washing and were infused via the peripheral vein. MNC characteristics were confirmed by fluorescence-activated cell sorting analysis (CD34, CD45, and c-kit). After ABMI therapy, liver function was monitored by blood examination for 24